jitendrajadhav/iStock via Getty Images
- Tandem Diabetes Care (NASDAQ:TNDM) said on Friday that its t:slim X2 insulin pump now works with Abbott’s (NYSE:ABT) FreeStyle Libre 3 Plus glucose monitor.
- The company has started an early access program in the U.S. and plans to expand availability in late 2025.
- The FreeStyle Libre 3 Plus sensor can be worn for 15 days and sends glucose readings to the pump every minute, the company said.
More on Tandem Diabetes Care, Abbott Laboratories
- Tandem Diabetes Care: A Barbell Bet On A High-Stakes Turnaround
- Abbott Laboratories: Why Wall Street’s Skepticism Misses The Real Story
- The Growth Of Medical Devices Needs To Continue In Order To Invest In Abbott
- Truist bullish on diabetes companies citing potential market growth
- Tandem, Abbott in deal to combine insulin delivery with glucose-ketone sensor